MannKind is seeking approval for diabetes inhaler system by spring
MannKind Corp. in Valencia is attempting to revolutionize the treatment of Type 1 and Type 2 diabetes with its first product: an inhaled form of insulin powder called Afrezza that would eliminate the need for most injections.